Good News for ITP Patients: Ianalumab + Eltrombopag Prolongs Time to Treatment Failure VS Eltrombopag Alone
Roger Schutgens, Professor of Thrombosis and Haemostasis at UMC Utrecht, shared on LinkedIn:
“Good news for patients with ITP.
Recently, the results of the VAYHIT2 trial have been published in The New England Journal of Medicine, showing that a course of B-cell–targeted therapy (ianalumab) combined with eltrombopag significantly prolongs time to treatment failure compared to eltrombopag alone in adults with immune thrombocytopenia after first-line steroids (13 months versus 4.7 months).
More patients were able to taper and discontinue eltrombopag (62% versus 39%), supporting the concept of early, disease-modifying treatment in ITP.
It was a joyfull ride to be part of this endeavor.”
Title: Ianalumab plus Eltrombopag in Immune Thrombocytopenia
Authors: Adam Cuker, Thomas Stauch, Nichola Cooper et al.
Read the full article.
Hemostasis Today has more posts you may find interesting.
-
Oct 5, 2026, 22:55Steve Humphreys: A Big Thank You to BSHT for Providing Me With a Recent Skills Exchange Award
-
Oct 5, 2026, 22:52William McKeown: Great to Be in Istanbul for the Opening of the EHC 2026
-
Oct 5, 2026, 22:48Laura Quintas Lorenzo: A New Approach to Healthcare for von Willebrand Disease at EHC 2026
-
Oct 5, 2026, 22:46Anas Zayad: Pleased to Share Our New Review on Thrombosis in SCD and Beta Thalassemia
-
Oct 5, 2026, 22:44Cihan Ay: Honouring Eric Kandel and Eugene Braunwald at the Medical University of Vienna
-
Oct 5, 2026, 22:42Heather L. Gornik: Testing for Aortic and Arterial Thrombosis at VSS 2026
-
Oct 5, 2026, 22:34Hasan Abbas Zaheer: Honoured to Have Co-Authored One of the Four Reviews in The Lancet Thalassemia Series
-
Oct 5, 2026, 22:34Kamyar Shameli: Understanding the Coagulation Cascade – How Anticoagulants Prevent Blood Clots
-
Oct 5, 2026, 22:31Risika Samanta: Pediatric ITP in a 12-year-old – An Atypical Presentation without a Viral Prodrome